PT  - JOURNAL ARTICLE
AU  - Lederman, Lynne
ED  - Langley, Ruth E.
TI  - Does Aspirin's Ability to Improve CRC Prognosis Depend on PIK3CA Mutation Status?
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 8--9
VI  - 14
IP  - 22
4099  - http://mdc.sagepub.com/content/14/22/8.short
4100  - http://mdc.sagepub.com/content/14/22/8.full
AB  - Aspirin may be an effective adjuvant treatment for patients with cancer; this has been suggested by long-term follow-up of randomized trials that were originally designed to determine the vascular effects of aspirin. This article discusses Add-Aspirin, a Phase 3 double-blind multicenter trial that will determine whether taking low-dose aspirin on a regular basis will improve the prognosis of patients who have recently undergone primary curative treatment for nonmetastatic colorectal, gastroesophageal, breast, or prostate cancer.